ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Comment by jjwilsonon May 12, 2017 4:20pm

93 Views

Post# 26239085

RE:RE:RE:RE:RE:RE:RE:RE:RE:Abridgment of warrants notice?

OK, well, I don't think it will happen. If I get written notification, or see a news release, that the execution period has been abridged I'll cut a cheque and buy the shares. If I can wait, I'll do that. I would expect the same from most who hold warrants although maybe I'm wrong. Maybe the warrants are already being executed by some since they're "in the money" now. I guess from a pure investment perspective I should execute the warrants at 20 cents and sell the shares immediately at 30 cents. However, since I don't see 30 cents as anywhere near the correct selling point I think I'll wait.

Bullboard Posts

Visionstate set to leverage success in the U.S. market